Invex Therapeutics (ASX:IXC) Long-Term Debt: A$0.00 Mil (As of Dec. 2025)


What is Invex Therapeutics Long-Term Debt?

Invex Therapeutics ASX:IXC Long-Term Debt is A$0.00 Mil as of Dec. 2025. The stock has 1 warning sign investors should review.

Invex Therapeutics's Long-Term Debt for the quarter that ended in Dec. 2025 was A$0.00 Mil.

Invex Therapeutics  (ASX:IXC) Long-Term Debt Explanation

Long-Term Debt is the sum of the carrying values as of the balance sheet date of all long-term debt, which is debt initially having maturities due after one year or beyond the operating cycle, if longer, but excluding the portions thereof scheduled to be repaid within one year or the normal operating cycle, if longer. Long-Term Debt includes notes payable, bonds payable, mortgage loans, convertible debt, subordinated debt and other types of long term debt.

Invex Therapeutics Long-Term Debt Related Terms

Invex Therapeutics Long-Term Debt Historical Data

* Premium members only.

The historical data trend for Invex Therapeutics's Long-Term Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Invex Therapeutics Long-Term Debt Chart

Invex Therapeutics Annual Data
Trend Jun20 Jun21 Jun22 Jun23 Jun24 Jun25
Long-Term Debt
Get a 7-Day Free Trial 0.00 0.00 0.00 0.00 0.00

Invex Therapeutics Semi-Annual Data
Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
Long-Term Debt Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00
Frequently Asked Questions Learn more about Long-Term Debt →
What does a Long-Term Debt of A$0.00 Mil mean?
Invex Therapeutics (ASX:IXC) has a Long-Term Debt of A$0.00 Mil as of Dec. 2025.
Is Invex Therapeutics' Long-Term Debt too high?
Invex Therapeutics' current Long-Term Debt is A$0.00 Mil.
How does Invex Therapeutics' Long-Term Debt compare to VRTX and REGN?
Invex Therapeutics' Long-Term Debt of A$0.00 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Long-Term Debt for a Biotechnology company?
A good Long-Term Debt depends on the Biotechnology industry context. However, Long-Term Debt should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Long-Term Debt mean?
A high Long-Term Debt can signal that a stock is expensive relative to its fundamentals. Invex Therapeutics's current Long-Term Debt is A$0.00 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Invex Therapeutics stock overvalued right now?
Invex Therapeutics (ASX:IXC) has a current Long-Term Debt of A$0.00 Mil. The current Long-Term Debt is A$0.00 Mil. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Long-Term Debt calculated?
Long-Term Debt is calculated from a company's financial statements. For Invex Therapeutics (ASX:IXC), the current Long-Term Debt is A$0.00 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Invex Therapeutics Business Description

Address c/- Automic Group, Level 5, 191 St Georges Terrace, Perth, WA, AUS, 6000
Invex Therapeutics Ltd is a biopharmaceutical company, focused on the repurposing of an already approved drug, Exenatide, for efficacious treatment of neurological conditions derived from or involving raised ICP including TBI, stroke and hydrocephalus. In addition, the Group has generated early-stage data on the use of Exenatide in the treatment of glaucoma, through the lowering of intraocular pressure in the eye. Geographically, it operates only in Australia.